Evidence map›Paper›PMID 36561065›Full record

ArticleRSC medicinal chemistry2022

Synthesis and evaluation of radiolabeled porphyrin derivatives for cancer diagnoses and their nonradioactive counterparts for photodynamic therapy.

Nur Izni Ramzi, Kenji Mishiro, Masayuki Munekane, Takeshi Fuchigami, Xiaojun Hu, Renata Jastrząb, Yoji Kitamura, Seigo Kinuya, Kazuma Ogawa

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in RSC medicinal chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Anticancer Activity of Ether Derivatives of Chrysin.Molecules (Basel, Switzerland) · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

Nur Izni RamziGraduate School of Pharmaceutical Sciences, Kanazawa University Kakuma-machi Kanazawa Ishikawa 920-1192 Japan kogawa@p.kanazawa-u.ac.jp.
Kenji MishiroInstitute for Frontier Science Initiative, Kanazawa University Kakuma-machi Kanazawa Ishikawa 920-1192 Japan.
Masayuki MunekaneGraduate School of Pharmaceutical Sciences, Kanazawa University Kakuma-machi Kanazawa Ishikawa 920-1192 Japan kogawa@p.kanazawa-u.ac.jp.
Takeshi FuchigamiGraduate School of Pharmaceutical Sciences, Kanazawa University Kakuma-machi Kanazawa Ishikawa 920-1192 Japan kogawa@p.kanazawa-u.ac.jp.
Xiaojun HuCenter for Molecular Recognition and Biosensing, School of Life Sciences, Shanghai University Shanghai 200444 China.
Renata JastrząbFaculty of Chemistry, Adam Mickiewicz University of Poznan Uniwersytetu Poznanskiego 8 Poznan 61-614 Poland.
Yoji KitamuraResearch Center for Experimental Modeling of Human Disease, Kanazawa University Takara-machi 13-1 Kanazawa Ishikawa 920-8640 Japan.
Seigo KinuyaDepartment of Nuclear Medicine, Kanazawa University Hospital, Kanazawa University Takara-machi 13-1 Kanazawa Ishikawa 920-8641 Japan.
Kazuma OgawaGraduate School of Pharmaceutical Sciences, Kanazawa University Kakuma-machi Kanazawa Ishikawa 920-1192 Japan kogawa@p.kanazawa-u.ac.jp.ORCID https://orcid.org/0000-0002-1691-7302
Kanazawa University · JPAdam Mickiewicz University in Poznań · PLKanazawa University Hospital · JPShanghai University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Radioiodinated porphyrin derivatives and the corresponding nonradioactive iodine introduced compounds, [

Identifiers

PMID36561065
PMCPMC9749959
OpenAlexW4297896910

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.